CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib.
Article Details
- CitationCopy to clipboard
De Buck S, Kucher K, Hara H, Gray C, Woessner R
CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib.
Biopharm Drug Dispos. 2018 Sep;39(8):394-402. doi: 10.1002/bdd.2157.
- PubMed ID
- 30171694 [ View in PubMed]
- Abstract
This study investigated the effect of itraconazole, a strong dual inhibitor of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), on the single dose pharmacokinetics of leniolisib. In order to differentiate the specific contribution of CYP3A from P-gp, the potential interaction with quinidine, a strong inhibitor of P-gp but not CYP3A, was studied as well. Using a fixed-sequence, 3-way crossover design, 20 healthy male subjects received single oral doses of 10 mg leniolisib during three phases separated by a washout: (1) leniolisib alone, (2) 200 mg itraconazole once daily for 9 days plus leniolisib on day 5, and (3) 300 mg quinidine administered 1 h before and 3 h after leniolisib. Itraconazole increased the leniolisib oral drug exposure (AUC(inf) ) by on average 2.1-fold, whereas the peak drug concentration (C(max) ) was less impacted (1.25-fold). The terminal elimination half-life (T(1/2) ) of leniolisib was also increased by ~2-fold. Neither oral AUC(inf) nor C(max) or T(1/2) was found to be altered by quinidine. These findings suggest that the interaction with itraconazole occurred mainly systemically through inhibition of CYP3A, and corroborate our in vitro findings that leniolisib is neither a sensitive CYP3A substrate nor a relevant in vivo substrate for intestinal or hepatic P-gp. Assuming itraconazole levels achieved complete inhibition of CYP3A, the fractional contribution of CYP3A to the overall disposition of leniolisib is estimated to be about 50%. The concomitant use of leniolisib with strong inhibitors of CYP3A as well as strong and moderate inducers of CYP3A is best avoided.
DrugBank Data that Cites this Article
- Drugs
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Leniolisib Cytochrome P450 1A1 Protein Humans NoSubstrateDetails Leniolisib Cytochrome P450 3A4 Protein Humans NoSubstrateDetails - Drug Reactions
Reaction Details Details
